Chemometec A/S
2.3.2026 10:50:21 CET | Globenewswire | Press release
Notification of managers’ transactions
Notification of managers’ transactions
ANNOUNCEMENT NO. 302
2 March 2026
Notification of managers’ transactions
ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.
See the transactions of the Member of ChemoMetec’s Board of Directors Betina Hagerup in the attached PDF document.
For further information, please contact:
Kim Nicolajsen, CFO
Telephone (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Eurocommercial Properties N.V.2.3.2026 12:26:28 CET | Press release
EUROCOMMERCIAL PROPERTIES N.V.: INVITATION TO THE FULL YEAR 2025 RESULTS CONFERENCE CALL AND WEBCAST
Novo Nordisk A/S2.3.2026 12:22:27 CET | Press release
Novo Nordisk A/S - share repurchase programme
Danmarks Skibskredit A/S2.3.2026 12:19:34 CET | Press release
Danish Ship Finance A/S appoints new CCO
Zymeworks Inc.2.3.2026 12:01:00 CET | Press release
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
RadNet, Inc.2.3.2026 11:45:00 CET | Press release
RadNet Acquires Gleamer, Making RadNet’s DeepHealth the Largest Provider of Radiology Clinical AI Solutions Worldwide
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom